Compliance of Initial Empiric Antimicrobial Therapy

Status Completed

Clinical Trial Summary

Hospital infections comprise about half of all undesirable complications related to hospital treatment. In case of bacterial infection administration of antimicrobial agent is a therapy of choice. For maximum effectiveness, antimicrobial agents should be administered quickly in optimal doses. Moreover, the therapeutic concentration of properly selected drugs should be achieved as soon as possible. The relation between delays in the administration of antibiotics and increased mortality is well known. That is why proper empiric therapy is so important. Before antimicrobial investigation is completed, which may last up to 72 hours, a wide-spectrum antimicrobial should be administered according to the type of infection, its origin, and the characteristics of the local pathogens.

The objective of this study is to compare the initial choice of empiric antimicrobial therapy and the results of both microbiological identification and susceptibility/resistance analysis of isolated pathogens.

This project was designed as a prospective cohort study. Analysis was performed in a large multidisciplinary academic hospital and trauma center. All decisions on empiric therapy with antimicrobial used in infections caused by multidrug-resistant pathogens, that are made in different hospital wards except intensive care, are required by hospital procedures to be confirmed by intensivists. In our analysis, the initial choice of empiric therapy in the hospital wards other than the critical care unit was compared with the results of microbiological investigations and susceptibility/resistance analyses of isolated pathogens.

Accurate microbial identification was performed with a VITEK® 2 automatic testing system. The microbroth dilution method with VITEK® 2 AST cards was used for the antibiotic susceptibility testing of isolated pathogens.

Microbiological analyses were performed between 2018 and 2020 according to the regulations of the European Committee on Antimicrobial Susceptibility (EUCAST, version 9.0, 2019) and the National Reference Centre for Susceptibility Testing (NRCST, Warsaw, Poland).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Anti-Infective Agents

Clinical Trial Details

NCT number	NCT04448665
Study type	Observational
Source	Military Institute of Medicine, Poland
Contact
Status	Completed
Phase
Start date	February 1, 2018
Completion date	February 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03279120` - Safety, PK, and PD Study of IVRs Releasing TFV and LNG	Phase 1
Not yet recruiting	`NCT03793946` - A Digital Antimicrobial Stewardship Smartphone Application to Combat AMR: the AB-assistant	N/A
Completed	`NCT01073540` - Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension	Phase 1
Completed	`NCT01073553` - Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules	Phase 1
Terminated	`NCT04489420` - Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM	Phase 1
Completed	`NCT01231763` - Acceptability Study of Vaginal Films for HIV Prevention	N/A
Completed	`NCT01244698` - Postoperative Antibiotic Requirements Following Immediate Breast Reconstruction	Phase 4
Active, not recruiting	`NCT04365101` - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19	Phase 1/Phase 2
Completed	`NCT01690533` - Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease
Completed	`NCT01105208` - Cross Over Study to Prove Bioequivalence Between Two Brands of Cefalexin Suspension	Phase 1
Recruiting	`NCT04310592` - Natural Killer Cell (CYNK-001) Infusions in Adults With AML	Phase 1
Completed	`NCT02046512` - Probiotics to Promote Intestinal Health	Phase 4
Completed	`NCT04210713` - Neuroimmune Dysfunction in Alcohol Use Disorder	Phase 1
Completed	`NCT05979207` - Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum	Phase 1
Recruiting	`NCT02242968` - Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.